Dendritic Cell Biomarker Assay for Skin Sensitization Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying the skin sensitizing potency of chemicals rely heavily on animal testing, which is inefficient and unethical, and existing in vitro alternatives lack the accuracy and reliability needed for predictive power, especially in correlating with human reactivity.
Innovation Solution
A method using dendritic cells to measure the expression of specific biomarkers, such as HIST1H2BM, to assess the skin sensitizing potency of test agents, providing a more reliable and accurate in vitro alternative by analyzing the transcriptome and applying multivariate models for predictive analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal testing methods (LLNA, GPMT) are used to identify skin sensitizing potency, then reliability and predictive power are maintained, but ethical concerns arise and the method is inefficient for large-scale chemical assessment
Solution Approach 1:
The patent replaces the mechanical/biological animal testing system with an in vitro cellular assay system. The human dendritic cell-based assay measures gene expression changes in response to chemical exposure, substituting animal models with human cell cultures to eliminate animal testing while maintaining predictive reliability for skin sensitization potency
Solution Approach 2:
The patent creates a simplified copy of the relevant biological system by using human dendritic cells in culture that replicate the key immunological responses of skin sensitization. This cellular model copies the essential features of the in vivo system without requiring whole animals, enabling ethical and efficient testing while preserving predictive power
2Object-affected harmful factors
If existing in vitro alternatives are used to replace animal testing, then animal testing is reduced, but accuracy and reliability for predicting human reactivity are insufficient
Solution Approach 1:
The patent improves measurement precision by changing the parameters measured in the in vitro assay. Instead of relying on simple cell viability or generic inflammatory markers, the assay measures specific gene expression changes (e.g., CD86, HLA-DR, CD40) in human dendritic cells, which are parameters directly relevant to skin sensitization mechanisms and correlate better with human reactivity
Solution Approach 2:
The patent introduces human dendritic cells as an intermediary between the test chemical and the measurement system. These cells serve as a biologically relevant mediator that processes chemical exposure and translates it into measurable gene expression changes, providing a more accurate bridge to human skin sensitization responses than existing in vitro methods
3Measurement precision
If comprehensive transcriptome analysis is performed to improve predictive power, then accuracy increases, but device complexity and cost increase
Solution Approach 1:
The patent extracts only the most relevant genes from the comprehensive transcriptome that are specifically involved in skin sensitization pathways. By focusing on a targeted subset of genes (e.g., immune response genes, antigen presentation genes) rather than analyzing all transcripts, the assay achieves high predictive power while reducing complexity compared to whole transcriptome analysis
Solution Approach 2:
The patent segments the complex transcriptome into functional modules or pathways relevant to skin sensitization. By dividing the gene expression analysis into specific biological pathways (e.g., MHC class II presentation, co-stimulation) rather than analyzing all genes simultaneously, the assay maintains high predictive accuracy while making the measurement system more manageable and less complex
Data Source
Figure 1A~1B
Figure 2A
Figure 2B
AI summary
The present invention relates to a method for identifying the skin sensitizer potency of a test agent, and arrays and analytical kits for use in such methods.